Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association
Insights
Cardiac sarcoidosis, an infiltrative cardiomyopathy, increasingly requires accurate diagnosis and management. This statement provides a framework for diagnosis and tiered treatment, prioritizing corticosteroids for active inflammation.
Area of Science:
- Cardiology
- Immunology
- Internal Medicine
Background:
- Cardiac sarcoidosis is an infiltrative cardiomyopathy caused by myocardial granulomatous inflammation.
- It presents with conduction disease, arrhythmias, and ventricular dysfunction, with increasing prevalence.
- Diagnostic uncertainty is common due to lack of definitive histological confirmation.
Purpose of the Study:
- To provide a framework for the diagnosis and management of cardiac sarcoidosis.
- To guide clinical practice and promote management conformity.
- To address the challenges posed by diagnostic uncertainty and lack of randomized trials.
Main Methods:
- Review of existing cohort studies and consensus opinions.
- Development of a diagnostic continuum for likelihood assessment.
- Proposal of a tiered treatment approach, starting with corticosteroids.
Main Results:
- Cardiac sarcoidosis diagnosis should be viewed as a continuum of probability, not binary.
- Treatment initiation is recommended for clinical manifestations with active inflammation.
- Corticosteroids are the first-line treatment, with management varying across centers.
Conclusions:
- A standardized framework is needed for diagnosing and managing cardiac sarcoidosis.
- Clinical judgment and a probabilistic approach are essential for diagnosis.
- Tiered, evidence-based management, starting with corticosteroids, is recommended.
Abstract:
Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium and may present with high-grade conduction disease, ventricular arrhythmias, and right or left ventricular dysfunction. Over the past several decades, the prevalence of cardiac sarcoidosis has increased. Definitive histological confirmation is often not possible, so clinicians frequently face uncertainty about the accuracy of diagnosis. Hence, the likelihood of cardiac sarcoidosis should be thought of as a continuum (definite, highly probable, probable, possible, low probability, unlikely) rather than in a binary fashion. Treatment should be initiated in individuals with clinical manifestations and active inflammation in a tiered approach, with corticosteroids as first-line treatment. The lack of randomized clinical trials in cardiac sarcoidosis has led to treatment decisions based on cohort studies and consensus opinions, with substantial variation observed across centers. This scientific statement is intended to guide clinical practice and to facilitate management conformity by providing a framework for the diagnosis and management of cardiac sarcoidosis.
Related Concept Videos
01:17Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
01:17Pathophysiology of Heart Failure
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:17Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
01:28Mechanism of Cardiac Arrhythmias